课题基金 / 基金详情

A Study on Mass-Screening Test for Detection of Bladder Cancer by Automated Urine Cytology

A Study on Mass-Screening Test for Detection of Bladder Cancer by Automated Urine Cytology
自动尿细胞学检测膀胱癌大规模筛查试验的研究
批准号:
01570907
负责人:
TACHIBANA Masaaki
金额:
$0.45万
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1989
资助国家:
日本
项目状态:
已结题
起止时间:
1989 至 1990

项目摘要

项目成果

TACHIBANA Masaaki的其他基金

相似基金

相关文献

中文摘要
翻译
在一些肿瘤系统中,肿瘤内异常脱氧核糖核酸(DNA)含量的存在与临床恶性程度明显存在直接相关性。现代流式细胞技术可以通过单个细胞检测,以极高的速度测量复杂细胞混合物中的DNA。因此,该分析方法可用于尿样中恶性细胞的定量、客观检测,可应用于尿细胞学自动化。为了评价流式细胞术DNA检测(FCM)对膀胱癌的诊断价值,对空尿细胞学、膀胱冲洗细胞学和膀胱冲洗FCM的敏感性进行了检测。对56例经组织学证实的膀胱移行细胞癌患者的76个样本的结果表明,流式细胞仪比空尿细胞学和/或膀胱洗涤细胞学更敏感。我们还发现FCM可能在尿细胞学检查显示出尿路上皮瘤变之前就预示着它,特别是在炎症背景下。因此,FCM被认为对疑似人群的病例发现或对诊断为膀胱癌的随访病例有价值。然而,由于检测低级别肿瘤的灵敏度较低,因此需要进一步发展和改进。因此,流式细胞术DNA/溴脱氧尿嘧啶(BrdU)双变量分析是否能比单独的DNA分析提供更多关于膀胱癌恶性潜能的信息。结果在56例膀胱肿瘤中,DNA/BrdU双色FCM可为膀胱癌恶性潜能的定量提供客观参数。因此,FCM技术比传统细胞学有优势,因为;1)更高的灵敏度;2)更早的可预测性;3)更客观和定量的分析。同时利用计算机辅助图像分析进行恶性肿瘤细胞检测。目前,该方法可以区分白细胞、红细胞、上皮细胞和晶体。此外,由于高核/细胞比例,可以识别高级别肿瘤细胞。然而,低级别肿瘤细胞难以明确。这一结果表明,需要进一步鉴定肿瘤特异性标志物,以改进该方法作为常规实验室程序。少
英文摘要
A direct correlation clearly exists between the presence of abnormal deoxyribonucleic acid (DNA) contents within the tumors and the degree of clinical malignancy in several tumor system. The modern flow cytometric technique can measure DNA in complex cell mixtures via individual cell examination at the tremendous rate. Therefore, this analysis can be uterized quantitative and objective detection of malignant cells in urine sample which can be applied to automated urine cytology. In order to evaluate flow cytometric DNA measurement (FCM) of bladder washing in the diagnosis of bladder cancer, the sensitivity of voided urine cytology, bladder washing cytology and bladder washing FCM was tested. The results from 76 samples from 56 patients with histologically proven transitional cell carcinoma of the bladder, FCM is more sensitive than voided urine cytology and/or bladder washing cytology. Also was found that FCM may indicate urothelial neoplasia before it is apparent on urine cytology, es … More pecially against a background of inflammation. Therefore, FCM is thought to be valuable for case finding in suspected population or for follow-up cases with diagnosed bladder cancer. However, potential developments of, and further improvements is needed since the sensitivity for detecting low-grade-tumor was low. In this regard, flow cytometric DNA/bromodeoxyuridine (BrdU) bivariate analysis was performed whether the technique can provide further information on the malignant potential of bladder cancer than DNA analysis alone. Results from a total of 56 bladder tumors, DNA/BrdU two-color FCM can provide an objective parameter for quantification of the malignant potential of bladder cancers. Thus, FCM technique is advantageous than classical cytology because of ; 1) higher sensitivity, 2) early predictability and 3) more objective and quantitative analysis. Meanwhile, malignant tumor cell detection by computer-assisted image analysis was performed. So far, the method can differentiate white blood cell, red blood cell, epithelial cell and crystals. Also, high-grade tumor cell can be identified because of high-nuclear/cell ration. However, difficulty of clarification on low-grade tumor cell were found. This result indicate that further identification of tumor-specific markers are needed for improvement of this method as routine laboratory procedures. Less
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
橘 政昭: "泌尿器系腫瘍におけるフローサイトメトリーによるDNA ploidy解析の意義" 慶應医学. (1991)
Masaaki Tachibana:“通过流式细胞术进行 DNA 倍体分析在泌尿系统肿瘤中的意义”Keio Medicine (1991)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaaki Tachibana,et al: "Quantification of cell kinetic characteristics using flow cytometric measurements of deoxyribonucleic acid and bromodeoxyuridine for bladder cancer" J.Urol. (1991)
Masaaki Tachibana 等人:“使用流式细胞术测量膀胱癌的脱氧核糖核酸和溴脱氧尿苷来量化细胞动力学特征”J.Urol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaaki Tachibana and Hiroshi Tazaki: "Clinical application of flow cytometric deoxyribonucleic acid Ploidy analysis in urological cancer" Proceedings of the international symposium on flow cytometry and image analysis for clinical application.(1991)
Masaaki Tachibana 和 Hiroshi Tazaki:“流式细胞术脱氧核糖核酸倍性分析在泌尿系统癌症中的临床应用”流式细胞术和图像分析临床应用国际研讨会论文集。(1991)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaaki Tachibana, Seido jitsukawa and Hiroshi Tazaki: "A comparative study of the sensitivity of bladder washing flow cytometry, voided urine cytology and bladder washing cytology in the detection of bladder carcinoma" Japanese Journal of Urology. 80. 10
Masaaki Tachibana、Seido jitsukawa 和 Hiroshi Tazaki:“膀胱冲洗流式细胞术、排泄尿细胞学和膀胱冲洗细胞学检测膀胱癌敏感性的比较研究”日本泌尿学杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 13 条
    Tumor specific immunotherapy using dendritic cells generated from allogeneic peripheral stem cell.
    • 批准号:
      14370520
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.22万
    • 财政年份:
      2002
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    HLA restricted tumor specific antigen epitope pulsed autologous dendritic cell vaccine treatment for hormone refractory prostate cancer
    • 批准号:
      12671557
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.56万
    • 财政年份:
      2000
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Induction of apoptosis against cytokine-producing urological cancer
    • 批准号:
      10671493
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      1998
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Establish mentofthe minimally invasive treatments based on biological characteristics for advanceduro logical cancers.
    • 批准号:
      07407046
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $14.21万
    • 财政年份:
      1995
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    海外基金